Fingerroot for Digestive Health and Functional Dyspepsia
Every traditional account of fingerroot starts in the same place: it is a digestive herb. Thai krachai is a folk remedy for flatulence, colic, and dyspepsia; Indonesian temu kunci goes into postpartum digestive tonics; Malay and Vietnamese practice use it as a warming stomachic. For most traditionally-used carminative herbs on this site, that is where the evidence trail stops — a name, a use, and no trial. Fingerroot is a partial exception. A Thai research group ran an actual randomised, placebo-controlled human trial in patients with functional dyspepsia, and it reported a positive result. That single trial, plus a small supporting body of animal gastroprotective work, makes digestive health the one claim area for fingerroot with human clinical data behind it — which is worth stating plainly, because it is easy to miss. The 2020–2022 antiviral research wave got the headlines; this got one modest trial in a mid-tier gastroenterology journal that few outside the field would have seen.
Table of Contents
- Traditional Carminative Use Across Southeast Asia
- The Functional Dyspepsia Trial — What Was Actually Tested
- How Much Weight One Trial Carries
- Gastroprotective and Anti-Ulcer Evidence in Animal Models
- Why a Bitter, Pungent Rhizome Would Plausibly Help Digestion
- The Hepatoprotective Side-Evidence
- What This Does Not Show
- Practical Considerations
- Cautions Specific to Digestive Use
- Key Research Papers
- Connections
Traditional Carminative Use Across Southeast Asia
A carminative is a substance traditionally used to relieve gas, bloating, and cramping by relaxing gut smooth muscle and encouraging the passage of trapped air — the same functional category as peppermint, fennel, and caraway in Western herbalism. Fingerroot occupies that role across four distinct Southeast Asian traditions, each arriving at it independently:
- Thai traditional medicine uses krachai for flatulence, colic, dyspepsia, and diarrhoea, and includes it in postpartum recovery formulas meant to "warm" the digestion after childbirth.
- Indonesian jamu uses temu kunci in postpartum tonics and in preparations for general digestive complaints, as part of the broader jamu tradition of warming, drying herbal blends.
- Malaysian folk practice uses the rhizome for coughs, mouth ulcers, and dry mouth, alongside digestive complaints.
- Chinese and Vietnamese folk practice both use it as a warming digestive, consistent with the broader Zingiberaceae family's reputation in East and Southeast Asian medicine.
Independent convergence across four traditions on the same functional claim is a mild point in fingerroot's favour — it suggests the plant does something noticeable when eaten, rather than the claim being invented once and copied. It is not evidence of efficacy by modern standards, and this page treats it as what it is: a consistent starting hypothesis, not a result.
The Functional Dyspepsia Trial — What Was Actually Tested
Functional dyspepsia is chronic upper-abdominal pain, fullness, early satiety, or bloating with no identifiable structural cause on endoscopy — one of the most common reasons adults see a gastroenterologist, and one of the hardest conditions to treat well, because the mainstay drug options (proton-pump inhibitors, prokinetics) help a meaningful minority of patients and often lose effect over time.
Chitapanarux and colleagues, working at Chiang Mai University in Thailand, ran a randomised, double-blind, placebo-controlled trial of fingerroot extract in patients with confirmed functional dyspepsia, published in Digestion in 2021. This is a real clinical trial with a placebo arm and blinding — the same evidentiary structure that gives the Vitamin A measles trials or the fingerroot skin trial their weight. Patients meeting Rome IV criteria for functional dyspepsia were randomised to standardised fingerroot extract or placebo capsules and followed for symptom response, using validated dyspepsia symptom severity scoring.
The trial reported that fingerroot extract produced a statistically significant improvement in dyspepsia symptom scores compared with placebo, with an acceptable safety profile and no serious adverse events attributed to the extract over the study period.
How Much Weight One Trial Carries
This is a genuinely positive, genuinely randomised, genuinely placebo-controlled human trial — rarer for a Southeast Asian traditional rhizome than almost any other claim on this page, and rarer than what exists for many far more heavily marketed supplements. It deserves to be taken seriously. It also deserves the same scrutiny this site applies to every single trial, positive or not:
- It is one trial. No independent group has yet attempted to replicate it. A single positive trial in a condition as notoriously placebo-responsive as functional dyspepsia — placebo response rates of 30–40% are typical in dyspepsia drug trials — is a reasonable basis for further research, not for a settled clinical claim.
- Functional dyspepsia is a symptom-based diagnosis with a subjective, patient-reported outcome. That does not invalidate the trial — validated symptom-severity instruments exist precisely to make such outcomes measurable and blinding-compatible — but subjective endpoints are inherently noisier than an objective lab value, and dyspepsia trials in general have a documented history of large placebo effects that shrink on replication.
- The extract was standardised and specific. The trial tested a defined fingerroot extract preparation at a defined dose. It did not test raw fingerroot, a kitchen-strength decoction, or the traditional postpartum drink, and because panduratin A is fat-soluble and poorly water-soluble (established on the main Fingerroot page), an extract and a water-based traditional preparation are not chemically interchangeable. Whether the effect would appear with a milder, food-level preparation is untested.
- The mechanism behind the clinical effect is not established. The trial demonstrates that the extract improved symptoms; it does not identify why. Candidate mechanisms — gastric emptying, visceral sensitivity, mucosal protection, an anti-inflammatory effect on gut mucosa — are plausible given fingerroot's other pharmacology, but none was measured in this trial.
The honest summary: this is the strongest single piece of clinical evidence fingerroot has for any indication, and it is still one trial that needs a second, independent, ideally larger confirmation before functional dyspepsia becomes an established use rather than a promising lead.
Gastroprotective and Anti-Ulcer Evidence in Animal Models
Beneath the human trial sits a small body of rodent gastroprotection research that predates it by roughly a decade, giving the dyspepsia result some preclinical context rather than leaving it to stand alone.
Abdelwahab and colleagues (2011) tested a methanolic extract of fingerroot and its major compound pinostrobin in a rat model of ethanol-induced gastric ulceration, reporting an anti-ulcerogenic effect attributed to indirect antioxidant action — reduced gastric lesion area and improved markers of oxidative stress in the stomach lining compared with untreated ulcer controls. Mohan and colleagues (2020) tested boesenbergin A, a chalcone isolated from fingerroot, in the same broad model — ethanol-induced gastric ulcer in vivo — and reported reduced oxidative stress and inflammation in the gastric mucosa.
Both studies are rodent, both use a chemical-injury ulcer model rather than a disease model of dyspepsia itself, and neither tests the standardised extract used in the human trial. What they establish is a plausible, mechanistically coherent gastroprotective signal — antioxidant and anti-inflammatory activity in gastric tissue — that sits comfortably alongside a positive dyspepsia trial without proving it. Gastric ulceration and functional dyspepsia are also not the same condition: an ulcer is a visible mucosal break; dyspepsia by definition has no structural lesion. A treatment that protects against one does not automatically treat the other, even if both plausibly share an anti-inflammatory, antioxidant mechanism.
Why a Bitter, Pungent Rhizome Would Plausibly Help Digestion
Traditional carminative herbs across unrelated cultures — peppermint, fennel, caraway, ginger, cardamom, fingerroot — share a chemical feature: they are rich in volatile essential oil components (monoterpenes, sesquiterpenes, and in fingerroot's case camphor, geraniol, and methyl cinnamate) that relax gastrointestinal smooth muscle in vitro and are bitter or pungent enough to stimulate salivary and gastric secretions on contact. This is a genuine, broadly reproducible pharmacological property of the terpene class as a whole, and it is the most defensible mechanistic story behind fingerroot's carminative reputation.
Two things temper that story. First, it is a property of the chemical class, not evidence specific to fingerroot — the same argument works equally well for ginger, cardamom, or galangal, and citing "terpenes relax gut smooth muscle" as if it were a fingerroot-specific finding would be a mild version of the compound-substitution error this site tries to avoid: the mechanism is real, but it is not exclusive. Second, traditional bitters carry their own contradiction worth naming here explicitly, because it recurs across this site's herb pages: bitter compounds are traditionally said to "stimulate" digestion and appetite, while modern human studies of bitter-receptor activation (TAS2R agonists) more often show reduced appetite and slowed gastric emptying — the opposite direction. Fingerroot has not been tested this way, so this is a caution about the general bitters narrative rather than a finding about fingerroot specifically, but it is a reason not to assume "traditional carminative" translates cleanly into a single, well-understood modern mechanism.
The Hepatoprotective Side-Evidence
A separate, more surprising body of work comes from one Malaysian research group (Salama and colleagues), who published a series of three studies between 2012 and 2018 testing fingerroot and panduratin A against thioacetamide-induced liver injury in rats — thioacetamide being a standard laboratory hepatotoxin used to model chronic liver damage and cirrhosis.
- Salama and colleagues (2012) reported that fingerroot treatment improved outcomes in a rat model of thioacetamide-induced liver cirrhosis.
- Salama and colleagues (2013) followed up with a mechanistic study of fingerroot's hepatoprotective effect in thioacetamide-induced liver damage, reporting reduced markers of liver injury and improved histology.
- Salama and colleagues (2018), by then testing panduratin A specifically rather than the whole extract, reported hepatoprotectivity against thioacetamide-induced cirrhosis, again in vivo in rats.
The liver is a digestive accessory organ, and antioxidant, anti-inflammatory hepatoprotection is mechanistically consistent with the same broad antioxidant story told throughout fingerroot's pharmacology — the same panduratin A and pinostrobin chemistry implicated in the gastric ulcer studies above. It is worth naming three real limits on this evidence. First, it is a single research group's output across three publications rather than three independently replicating groups, so treat it as one continuous line of work rather than three separate confirmations. Second, thioacetamide hepatotoxicity is a model of acute-to-chronic chemical poisoning, not of any human liver disease a reader is likely to have (viral hepatitis, alcohol-related liver disease, fatty liver) — it demonstrates antioxidant hepatoprotection against a specific toxic insult, and that does not automatically transfer to a different kind of liver injury. Third, this remains entirely rodent work; no human liver-outcome data exists for fingerroot in any form. It is included here as an honest part of the digestive-system evidence picture, not as a reason to reach for fingerroot for any actual liver condition, which requires medical evaluation regardless.
What This Does Not Show
Naming the gaps directly, because absence of a specific finding is itself informative:
- No dose-finding study exists. The dyspepsia trial used one dose of one standardised extract. There is no data comparing doses, no established minimum effective dose, and no data on whether more extract produces more benefit or simply more side effects.
- No trial has tested the traditional preparation — a fresh-rhizome decoction or the honey-lime drink — for any digestive endpoint. Every controlled finding on this page used either an extract or an isolated compound.
- No mechanism study accompanied the human trial. Gastric emptying, visceral hypersensitivity, and gut microbiome composition were not measured, so the "why" behind the dyspepsia result is inferred from separate, older rodent ulcer work rather than demonstrated directly.
- No trial exists for irritable bowel syndrome, gastroesophageal reflux, or any other common digestive complaint — only functional dyspepsia has trial data, and the traditional use is broader than that (flatulence, colic, diarrhoea) than the one condition that has actually been tested.
- No replication. Repeated for emphasis because it is the single most important open question: an independent group has not yet reproduced the Chitapanarux result.
Practical Considerations
Because no dose-finding study exists, there is no way to state a therapeutic dose with any confidence — a limitation this site states rather than guesses past. What can be said:
- Food-level use — fingerroot shredded into jungle curry, stir-fries, or fish dishes at the quantities described on the main Fingerroot page (roughly 20–50 g per dish) — has a long history of safe culinary use and is a reasonable way to include the traditional carminative in the diet without extrapolating from clinical-trial doses.
- The traditional honey-lime drink made from a few fresh fingers blended with water is likewise traditional practice with a long safety record, though (as above) it delivers very little of the fat-soluble panduratin A and its effect, if any, would not be explained by the same chemistry as the extract trial.
- A standardised extract product, if someone specifically wants to approximate the trial conditions, should at minimum state the species (Boesenbergia rotunda, sometimes still labelled Boesenbergia pandurata) and the extraction method on the label. Nothing on this page should be read as a specific dosing recommendation, because none exists in the literature.
- Persistent dyspepsia symptoms warrant medical evaluation before self-treatment with any herbal product, because functional dyspepsia is a diagnosis of exclusion — the same symptoms can signal peptic ulcer disease, H. pylori infection, gastroesophageal reflux, gallstones, or, less commonly, gastric malignancy, all of which need to be ruled out by a clinician rather than assumed away.
Cautions Specific to Digestive Use
- Do not substitute fingerroot for medical evaluation of new or worsening digestive symptoms — particularly weight loss, difficulty swallowing, vomiting blood, black stools, or symptoms starting after age 50, which are alarm features that need prompt investigation, not a trial of an herbal extract.
- The one supportive trial found an acceptable safety profile over its study period, but that period was short and the sample was one trial's worth of patients — it is not a substitute for longer-term human safety data, which does not exist for concentrated fingerroot extracts.
- Reflux and gallbladder disease — noted on the main Fingerroot page — deserve a second mention here specifically: a pungent, bile-stimulating rhizome taken as a concentrated extract could plausibly aggravate reflux or biliary colic in a susceptible person, even though this has not been formally studied.
- Pregnancy and breastfeeding: food amounts are fine; concentrated extracts — including any product resembling the dyspepsia-trial formulation — are unstudied in pregnancy and lactation and should be avoided outside of medical supervision, notwithstanding fingerroot's traditional postpartum use, which is history rather than a safety clearance.
Key Research Papers
- Chitapanarux T, Lertprasertsuke N, Toworakul C (2021). Efficacy and Safety of Fingerroot (Boesenbergia rotunda) Extract in Patients with Functional Dyspepsia: A Randomized, Placebo-Controlled Trial. Digestion, 102(4):599–606. — PubMed
- Abdelwahab SI, Mohan S, Abdulla MA, et al. (2011). The methanolic extract of Boesenbergia rotunda and its major compound pinostrobin induces anti-ulcerogenic property in vivo. Journal of Ethnopharmacology, 137(2):963–70. — PubMed
- Mohan S, Hobani YH, Shaheen E, et al. (2020). Ameliorative effect of Boesenbergin A, a chalcone isolated from Boesenbergia rotunda, on oxidative stress and inflammation in ethanol-induced gastric ulcer in vivo. Journal of Ethnopharmacology, 261:113104. — PubMed
- Rosdianto AM, Puspitasari IM, Lesmana R, et al. (2020). Inhibitory Activity of Boesenbergia rotunda Rhizome towards the Expression of Akt and NF-KappaB p65 in Acetic Acid-Induced Wistar Rats. Evidence-Based Complementary and Alternative Medicine, 2020:6940313. — PubMed
- Salama SM, Bilgen M, Al Rashdi AS, et al. (2012). Efficacy of Boesenbergia rotunda Treatment against Thioacetamide-Induced Liver Cirrhosis in a Rat Model. Evidence-Based Complementary and Alternative Medicine, 2012:137083. — PubMed
- Salama SM, Abdulla MA, Alrashdi AS, et al. (2013). Mechanism of Hepatoprotective Effect of Boesenbergia rotunda in Thioacetamide-Induced Liver Damage in Rats. Evidence-Based Complementary and Alternative Medicine, 2013:157456. — PubMed
- Salama SM, Ibrahim IAA, Shahzad N, et al. (2018). Hepatoprotectivity of Panduratin A against liver damage: In vivo demonstration with a rat model of cirrhosis induced by thioacetamide. APMIS, 126(9):710–721. — PubMed
- Wang Y, Wen J, Liu F, et al. (2025). Traditional usages, chemical metabolites, pharmacological activities, and pharmacokinetics of Boesenbergia rotunda: a comprehensive review. Frontiers in Pharmacology, 16:1527210. — PubMed
- Techapichetvanich P, Tangpanithandee S, Supannapan K, et al. (2024). Oral sub-chronic toxicity of fingerroot (Boesenbergia rotunda) rhizome extract formulation in Wistar rats. Toxicology Reports, 12:224–233. — PubMed
- Choi S, Kim C, Son H, et al. (2020). Estimation of an Appropriate Human Dose of Boesenbergia pandurata Extracts Based on Allometric Scaling Data of Panduratin A in Mice, Rats, and Dogs. Journal of Medicinal Food, 23(4):453–458. — PubMed